| HS Code | 204314 |
| Product Name | Avian Influenza (Subtype H9) Vaccine, Inactivated (Strain LG1) Veterinary Grade API |
| Api Category | Veterinary vaccine bulk antigen |
| Pathogen | Avian influenza virus subtype H9 |
| Strain | LG1 |
| Vaccine Type | Inactivated whole virus vaccine |
| Inactivation Method | Chemically inactivated with formaldehyde or beta-propiolactone |
| Antigen Content | Inactivated avian influenza H9 virus antigen concentrate |
| Adjuvant Compatibility | Can be formulated with oil emulsion or aluminum hydroxide adjuvant |
| Target Species | Poultry including chickens, ducks, and turkeys |
| Route Of Administration | For injection after formulation; final dosage forms may support subcutaneous or intramuscular administration |
| Dosage Form Compatibility | Tablets, injections, capsules, powders, granules, premix, and solutions |
| Storage Conditions | Store at 2 to 8 degrees Celsius, protected from light and freezing |
| Shelf Life | 24 months from date of manufacture under recommended storage conditions |
| Withdrawal Period | Zero days when used in accordance with label instructions |
| Regulatory Reference | Veterinary pharmacopoeia and OIE standards for inactivated avian influenza vaccines |
As an accredited Avian Influenza(Subtype H9)Vaccine,Inactivated(Strain LG1) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged as sterile, sealed multi-dose vials containing 100 mL inactivated avian influenza vaccine, veterinary grade, for injection use only. |
| Container Loading (20′ FCL) | One 20′ FCL containing palletized, temperature-controlled vaccine API cartons, securely loaded and sealed for safe transport. |
| Shipping | Ship as regulated veterinary biological material under cold chain (2–8°C), protected from light and freezing. Use validated insulated packaging with temperature monitors. Comply with IATA/ADR dangerous goods if applicable. Include veterinary API documentation, SDS, and chain-of-custody records for customs and regulatory clearance. |
| Storage | Store under refrigerated conditions at 2–8°C. Protect from light and moisture. Do not freeze. Keep in tightly sealed, original container away from direct sunlight and heat sources. Ensure adequate ventilation and maintain clean, dry conditions. For bulk API powders/granules, use appropriate handling procedures to prevent contamination and loss of potency. Follow veterinary pharmacopoeial guidelines. |
| Shelf Life | Shelf life is typically 12 months when stored refrigerated at 2–8°C, protected from light, and never frozen. |
Production-scale utilization of inactivated H9 subtype avian influenza antigen, strain LG1, is centered on sterile liquid vaccine intermediates and injectable finished emulsions. The antigen concentrate is a killed whole-virus suspension, not a dry chemical powder; it requires chilled transfer, aseptic dilution, and adjuvant-driven presentation. In the most common downstream route, the concentrate is thawed from -20°C or -70°C to 4–8°C under a controlled biological-manufacturing environment before formulation. The aqueous phase is prepared by diluting the concentrate in phosphate-buffered saline at pH 7.2–7.4, with osmolality adjusted to 280–320 mOsm kg⁻¹; the final dose volume for subcutaneous or intramuscular use in replacement layers and breeders is set by the marketing authorization, commonly 0.3–0.5 mL per bird. Emulsification is performed by adding the aqueous phase to a light mineral oil/emulsifier system at a phase mass ratio of approximately 30:70, using an inline rotor-stator homogenizer at 3,000–6,000 rpm followed by a second pass under controlled back pressure until laser diffraction analysis shows Dv90 below 5 µm. Batches with Dv90 above 10 µm exhibit creaming during accelerated stability testing and are reworked before filling. The finished emulsion is not sterile-filtered after emulsification because the dispersed phase exceeds membrane pore size; sterility is maintained by pre-filtration of the aqueous antigen phase through a 0.22 µm or 0.45 µm PES or PVDF membrane validated for the specific particle size distribution, sterilization of the oil phase, and aseptic filling. Viscosity at 25°C and 100 s⁻¹ is controlled within 25–80 mPa·s to permit transfer through vial-filling nozzles without shear-induced droplet breakdown. The terminal product is a 100 mL or 250 mL polypropylene or glass vial for subcutaneous or intramuscular injection. Release testing references Ph. Eur. 2.6.1, USP 71, Ph. Eur. 2.2.3, Ph. Eur. 2.2.35, ISO 13320:2020, and potency standards described in WOAH Manual Chapter 3.3.4 and USDA 9 CFR 113.49. Freezing of the finished emulsion is avoided because phase separation occurs on thawing. Published LG1-specific droplet-size optimization data is limited; the Dv90 limits above derive from emulsion physical stability rather than strain-specific immunogenicity trials.
| In-process control point | Method or standard |
|---|---|
| Sterility of aqueous antigen phase | Ph. Eur. 2.6.1 / USP 71 |
| pH of aqueous phase and final emulsion | Ph. Eur. 2.2.3 |
| Osmolality of aqueous phase | Ph. Eur. 2.2.35 |
| Droplet size distribution of emulsion | ISO 13320:2020 |
| Emulsion viscosity | ISO 3219:2021 |
| Residual moisture in lyophilized reference antigen | Ph. Eur. 2.5.12 |
Combination vaccines containing H9 LG1 antigen are produced by incorporating the aqueous antigen concentrate into a pooled antigen phase that may include inactivated Newcastle disease virus, infectious bronchitis virus, egg drop syndrome virus, avian reovirus, and certain bacterial antigens. The H9 component is typically diluted to 15–35% v/v of the total aqueous antigen pool, but the exact ratio is set by HA titre and final dose volume; published data for strain LG1-specific multivalent ratio optimization is limited. The blending sequence is designed to avoid local pH excursions below 6.8 or above 7.6, because the H9 hemagglutinin is sensitive to acid-induced conformational changes that reduce measurable HA titre. Each antigen stream is pre-equilibrated to 2–8°C, and the H9 concentrate is first diluted into the aqueous buffer before other antigen streams are introduced. Hold time after blending and before emulsification is limited to 4–6 h at 2–8°C; longer hold times increase adsorption to polymer surfaces and titre loss. The terminal product is a multivalent injectable emulsion for replacement layers and breeders, filled into 100 mL or 250 mL bottles. Release testing includes Ph. Eur. 2.6.1, USP 71, Ph. Eur. 5.1.3 preservative effectiveness testing where a multidose container is used, WOAH Manual Chapter 3.3.4 potency, and USDA 9 CFR 113.49 safety and potency. Addition of H9 antigen to an already formed oil emulsion is not recommended because phase inversion and droplet coalescence can occur; the antigen must be present in the aqueous phase before emulsification.
For regional antigen banks and emergency supply programs, the concentrated LG1 antigen is processed as a sterile aqueous intermediate rather than as a finished oil emulsion. Ultrafiltration through a 100 kDa cassette against phosphate-buffered saline concentrates the antigen and removes low-molecular-weight residuals; the concentrate is then passed through a 0.22 µm PES or PVDF membrane under Grade A aseptic conditions and filled into single-use polymer bags or polypropylene bottles. Preserved bulk can be stored at 2–8°C for up to 24 months when thiomersal is present at 0.01% w/v or formaldehyde is maintained within registered residual limits, subject to batch-specific real-time stability data. If frozen at -20°C or -70°C, the intermediate is limited to a single thaw cycle; repeated freezing of orthomyxovirus antigen suspensions can reduce hemagglutination titre by up to 1 log2 per cycle, although LG1-specific freeze-thaw data is limited. At the downstream vaccine bank facility, the concentrate is diluted with sterile PBS to the working HA titre and emulsified with the regionally approved oil adjuvant. The final product is identical in presentation to commercial injectable emulsion vaccine, with a dose volume of 0.3–0.5 mL. Compliance for this intermediate includes EU GMP Annex 2 Part IV for biological active substances, Ph. Eur. 2.6.1 sterility, Ph. Eur. 2.6.14 endotoxin, Ph. Eur. 2.2.3 pH, and ISO 9001 quality management for storage and distribution. This route is used where finished emulsion cold-chain capacity is limited and regional authorities permit local emergency blending.
Reference antigen for hemagglutination inhibition batch-release controls and diagnostic serology panels is generated by lyophilizing the inactivated H9 LG1 antigen in a stabilizer matrix. A solution of 5–10% w/v trehalose or sucrose in phosphate buffer is blended with the antigen at a 1:1 v/v ratio, filled at 0.5–1.0 mL per 2 mL glass vial, and frozen at -40°C for 4–6 h. Primary drying is conducted at -20°C to -10°C under 0.1 mbar chamber pressure for 24–48 h, followed by secondary drying at 20°C until residual moisture by Karl Fischer is below 3% w/w. Lyophilization can reduce HA titre by 0.5–1 log2; therefore this format is reserved for analytical reference material and is not used as a commercial finished vaccine. Reconstitution with sterile water for injection restores the antigen for HI plate use within 2–4 h at 4°C. The terminal product is a sealed lyophilized plug in a glass vial, with overage added to compensate for titre loss. Compliance includes Ph. Eur. 2.6.1 sterility, Ph. Eur. 2.5.12 water content, and ISO 9001 production documentation for reference materials. Published data specific to LG1 lyophilization matrices is limited; the trehalose and sucrose ranges above derive from orthomyxovirus reference antigen stabilization work and must be confirmed during process validation.
Regional filling campaigns using approved ready-to-emulsify adjuvants receive LG1 antigen as a concentrate rather than a pre-blended aqueous phase. The concentrate is diluted into sterile PBS and combined with an approved mineral-oil adjuvant such as Montanide ISA 70 VG or ISA 71 VG at a final aqueous-to-oil phase mass ratio of 30:70. A single-step high-shear protocol using an inline rotor-stator mixer at 3,000–6,000 rpm yields a monovalent injectable emulsion with Dv90 below 5 µm. The terminal product is filled as 0.3–0.5 mL doses in polypropylene bottles. Compliance at the regional site includes EU GMP Annex 2 Part IV or equivalent national biological product GMP, Ph. Eur. 2.6.1 sterility, Ph. Eur. 2.2.3 pH, ISO 13320:2020 droplet size measurement, and real-time stability testing under applicable climatic zone conditions. This route does not involve antigen stockpiling; the antigen is consumed within the same filling campaign following release.
Although the broad raw-material specification lists solid oral dosage forms, inactivated H9 LG1 antigen is not formulated into tablets, capsules, powders, granules, or feed premix as a commercial immunogenic product. Acid denaturation in the poultry proventriculus, proteolytic digestion in the intestinal lumen, and the absence of effective mucosal immune induction by killed whole-virus antigen prevent oral solid formulations from meeting veterinary vaccine efficacy standards. No pharmacopoeial monographed oral solid dosage form exists for inactivated avian influenza vaccine antigen, and the finished dosage form remains an injectable sterile liquid or emulsion. Solutions may serve as aqueous dilution intermediates, but not as oral or environmental treatments. The mixing, compression, granulation, and premix ratios applied to chemical active ingredients are therefore not transferable to this antigen.
Competitive Avian Influenza(Subtype H9)Vaccine,Inactivated(Strain LG1) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Avian Influenza (Subtype H9) Vaccine, Inactivated (Strain LG1) is a veterinary-grade antigen concentrate intended for downstream formulation of killed avian influenza vaccines. The strain designation LG1 identifies a low-pathogenic H9 subtype isolate, typically handled as an H9N2 lineage antigen for chickens and related poultry. The model designation is the master seed identifier LG1; the API is supplied as an aqueous suspension or lyophilized powder for further manufacture, not as a finished dose. The product is classified as a veterinary-grade active pharmaceutical ingredient for tablets, injections, capsules, powders, granules, premix, and solutions; however, the listed dosage forms are physical presentation options for the antigen or its diluents, and they are not equivalent routes of immunization. The established route for the inactivated whole-virus antigen is parenteral injection after oil-adjuvant emulsification. Published data on oral solid or feed-based administration of inactivated H9 antigen is limited.
Because the product is a bulk antigen rather than a finished vaccine, the release profile is defined by identity, safety, and potency measurements. The WOAH Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 3.3.4, supplies the reference methods for subtype identity confirmation and inactivation efficacy. Publicly available batch data for the LG1 seed lot is limited; therefore thresholds cited below are drawn from general published acceptance ranges for inactivated H9 antigen concentrates unless the manufacturer’s certificate of analysis specifies otherwise.
Identity is confirmed by hemagglutination inhibition using H9 monospecific antiserum. The test antigen is adjusted to a working hemagglutination titer, and the hemagglutination inhibition titer is read against a reference antigen. A result within one dilution of the reference titer is generally accepted. Strain LG1 is an H9 subtype isolate; the master seed report should include HA and NA gene accession numbers where available, passage history, and confirmation of subtype identity before release of the working seed.
The antigen is produced in 9- to 11-day-old specific-pathogen-free embryonated chicken eggs. After inoculation and incubation at 35–37 °C for 48–72 h, allantoic fluid is harvested and clarified by continuous-flow centrifugation. The virus is concentrated and then chemically inactivated. Inactivation agent and contact time are manufacturer-validated. Residual infectivity is tested by two blind passages in specific-pathogen-free embryonated eggs. The absence of embryo mortality and hemagglutinating activity in the second passage is required. Published data for LG1-specific inactivation kinetics is limited; the process must nevertheless demonstrate a reduction below the detection limit of the egg passage test.
Sterility is assessed by direct inoculation of the bulk antigen into fluid thioglycollate medium and soybean-casein digest medium. Incubation proceeds for 14 days at 30–35 °C and 20–25 °C, respectively. Absence of bacterial and fungal growth is required. Endotoxin content for parenteral veterinary antigens may be controlled by the manufacturer; where specified, a common release limit is <0.5 EU per finished dose using Limulus amebocyte lysate testing according to Ph. Eur. 2.6.14. Aqueous liquid presentations are inspected for opalescence; pH is commonly specified between 7.0 and 7.6 to preserve hemagglutinin conformation. Lyophilized presentations are examined for cake integrity and residual moisture; a residual moisture limit of <5.0% is commonly applied to freeze-dried veterinary antigen powders, though manufacturer-specific limits may vary.
The hemagglutination titer is a critical potency surrogate. For inactivated H9 antigen concentrates, pre-inactivation hemagglutination titers of 1:256 to 1:2048 per 0.1 mL are commonly reported; the manufacturer sets the minimum release titer based on immunogenicity studies. For lyophilized powder, the hemagglutination titer is determined after reconstitution.
| Test parameter | Typical acceptance criterion | Reference method |
|---|---|---|
| Identity | H9 subtype confirmed by hemagglutination inhibition with monospecific antiserum | WOAH Chapter 3.3.4 |
| Inactivation efficacy | No live virus after two blind passages in 9- to 11-day-old SPF eggs | WOAH Chapter 3.3.4 |
| Sterility | No bacterial or fungal growth after 14 days | Ph. Eur. 2.6.1 / 9 CFR 113.26 |
| Hemagglutination titer | Minimum release titer set by manufacturer; commonly ≥1:256 | WOAH Chapter 3.3.4 |
| pH | 7.0–7.6 for aqueous liquid | Ph. Eur. 2.2.3 |
| Residual moisture | <5.0% for lyophilized powder unless otherwise specified | Ph. Eur. 2.2.32 |
| Endotoxin | <0.5 EU per finished dose where specified | Ph. Eur. 2.6.14 |
During inactivation, the chosen agent is added under mixing and the reaction is held at a temperature that balances reaction rate with antigen stability. Formaldehyde inactivation of influenza viruses is slower at 4 °C than at 25 °C; however, exposure to elevated temperature can reduce hemagglutination titer. Manufacturers therefore validate a kill curve by sampling at multiple time points and plotting log₁₀ infectivity against contact time. The process is accepted when a reduction of at least 10 log₁₀ EID₅₀ is demonstrated and the two-passage egg test is negative. Downstream purification removes non-viral egg proteins that can contribute to injection-site reactions. Clarified allantoic fluid is concentrated by tangential-flow filtration with a molecular weight cutoff selected to retain virus particles while removing low-molecular-weight egg proteins. A 0.2 µm filtration step is used only if the process stream supports it; whole influenza virions are pleomorphic and can be sensitive to shear. Filtration can reduce antigen recovery if the viral particles aggregate, so manufacturers often add a stabilizer such as gelatin or sucrose before filtration. Because LG1-specific recovery data is not publicly available, filter sizing must be confirmed on a trial batch.
Production-scale processing of the LG1 antigen is constrained by shear and temperature. If the antigen is emulsified into a mineral oil adjuvant, the aqueous antigen phase and the oil phase are equilibrated at 15–25 °C before mixing. A rotor-stator homogeniser or high-shear mixer generates a water-in-oil emulsion; the temperature at the homogeniser head is held below 37 °C to avoid haemagglutinin denaturation. Emulsion droplet size is measured by laser diffraction and is typically controlled below 1 µm median diameter to ensure a stable depot and acceptable syringeability. Viscosity of the finished injectable is usually assessed at 25 °C; many oil-emulsion poultry vaccines are released at 20–80 cP, but manufacturer-specific data for LG1 may differ. Inactivated H9 vaccines are injected subcutaneously or intramuscularly, commonly at 0.3–0.5 mL per bird; published LG1-specific dose confirmation is limited.
Aqueous solution presentation is limited to short-term reconstitution or in-factory dilution. Phosphate-buffered saline at pH 7.2–7.4 can be used for reconstitution of lyophilized antigen, but the working dilution should be held at 2–8 °C and used within 24 h unless a manufacturer-specific stability study supports a longer hold. Without an oil adjuvant, an aqueous injection produces a weaker and shorter-lived antibody response; therefore the solution form is an intermediate rather than a final vaccine presentation.
Tablets, capsules, powders, granules, and premix presentations of the inactivated antigen are physically feasible only under cold-chain lyophilization and anhydrous packaging. The HA glycoprotein is acid-labile; after ingestion, the proventricular and gizzard environment at pH below 3.0 denatures the antigen before it can reach gut-associated lymphoid tissue. Feed mixing also exposes the antigen to ambient temperatures above the cold-chain range. Published challenge-protection data for oral administration of inactivated H9 whole-virus antigen is limited, and no commercial inactivated avian influenza vaccine for oral solid delivery has been validated under a recognized pharmacopoeial or WOAH standard. Consequently, these dosage forms should not replace the injectable oil-emulsion route.
The bulk antigen should be stored at 2–8 °C as an aqueous suspension and protected from freezing unless the manufacturer’s stability data demonstrates that freezing does not reduce hemagglutination titer. Freeze-thaw cycles can shear the viral envelope and release nucleic acid into the suspending medium, altering viscosity and antigen integrity. Lyophilized powder should be sealed under nitrogen and stored at 2–8 °C; after reconstitution, it should be used promptly.
Compared with live recombinant H9 vector vaccines, the inactivated whole-virus LG1 product does not replicate, does not shed vaccine virus, and cannot return to virulence. This reduces flock-to-flock transmission risk and is preferred in regions where live avian influenza vaccine use is restricted. The limitations are a slower onset of immunity and the requirement for two doses. A prime at 3–6 weeks of age followed by a second dose 3–4 weeks later is common for H9N2 inactivated vaccines; the second dose is necessary because the oil-adjuvant depot releases antigen slowly and a single exposure often fails to produce a persistent hemagglutination inhibition titer.
Compared with subunit or recombinant hemagglutinin-only products, the whole-virus antigen retains neuraminidase and internal proteins. This can supply additional T-cell epitopes and may support diagnostic differentiation, but protection against clinical disease remains primarily driven by HA-specific antibody. A field strain with a drifted receptor-binding pocket can evade hemagglutination inhibition antibody even when the internal proteins are conserved. Consequently, seed matching by hemagglutination inhibition testing against circulating H9N2 isolates is required before vaccination.
Strain LG1 is not antigenically identical to all H9N2 field strains. Published data quantifying the antigenic distance between LG1 and the main H9N2 lineages, including G1 and Y280, is limited. A twofold difference in hemagglutination inhibition titer may be within assay variability, but a fourfold or greater difference is generally considered antigenically significant. Therefore strain selection should not be made on the basis of the H9 subtype alone. Without periodic cross-hemagglutination inhibition testing, no inactivated H9 antigen of any strain can be assumed to give universal coverage. The manufacturer’s seed report should provide the passage history, HA and NA gene accession numbers where available, and confirmation of the H9 subtype.
